Page results
-
UCLH NHS Foundation Trust has once again formed a partnership with the Business Design Centre in Islington to reopen a large-scale COVID-19 vaccination centre on site from Saturday 18 December.
-
University College London Hospitals (UCLH) is now administering new COVID-19 treatments for patients at highest risk in the community.
-
Having proton beam therapy: information for children aged 5- 8 patient information leaflet
-
Having proton beam therapy: information for children aged 9-12 patient information
-
This page has been written for patients who are having radioactive iodine (131I) ablation and/or radioiodine treatment for thyroid cancer.
-
This page is for parents and carers whose child is having radiotherapy treatment to the pelvis.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the spine (backbone).
-
This page has been written for parents and carers whose child is having total body irradiation (TBI) for leukaemia, lymphoma, or some other rare blood disorder.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the whole brain and spine. This treatment may also be referred to as whole central nervous system (CNS) or cranio-spinal radiotherapy.
-
Having proton beam therapy: information for teenagers aged 13-17 patient information
File results
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments